Search results for "recurrence"

showing 10 items of 1036 documents

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia

2017

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia

OncologyAdultMaleCancer Researchmedicine.medical_specialtyMyeloidAdolescentmedicine.medical_treatmentSalvage therapyHematopoietic stem cell transplantationOutcome (game theory)03 medical and health sciencesYoung Adult0302 clinical medicineText miningRecurrencehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansYoung adultLetter to the EditorAgedAged 80 and overSalvage Therapybusiness.industryHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyMiddle Agedmedicine.diseasePrognosisLeukemiaLeukemia Myeloid Acutemedicine.anatomical_structureTreatment OutcomeOncology030220 oncology & carcinogenesisFemalebusiness030215 immunologyLeukemia
researchProduct

Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer.

2013

International audience; OBJECTIVE: To explore the risk of new or recurrent cancer among patients with IBD and previous cancer, exposed or not to immunosuppressants. DESIGN: Among the 17 047 patients of the CESAME prospective observational cohort who were enrolled from May 2004 to June 2005, and followed-up until December 2007, we identified 405 patients with cancer diagnosed previous to study entry. We calculated the rates of incident cancer in patients with or without previous cancer, and we assessed by survival analysis and nested case-control study the impact of immunosuppressants on the risk of incident new or recurrent cancer in patients with previous cancer. RESULTS: The rate of incid…

OncologyAdultMalemedicine.medical_specialtyAzathioprineKaplan-Meier EstimateCrohn Disease[ CHIM.ORGA ] Chemical Sciences/Organic chemistryRisk FactorsInternal medicineNeoplasmsEpidemiology of cancermedicineHumansProspective StudiesSurvival analysisAgedProportional Hazards ModelsCrohn's diseasebusiness.industry[CHIM.ORGA]Chemical Sciences/Organic chemistryIncidence (epidemiology)IncidenceGastroenterologyCancerMiddle Agedmedicine.diseaseUlcerative colitis3. Good healthSurgeryCase-Control StudiesCohortMultivariate AnalysisColitis UlcerativeFemaleNeoplasm Recurrence LocalbusinessImmunosuppressive Agentsmedicine.drugFollow-Up Studies
researchProduct

Surrogate end points for overall survival and local control in neoadjuvant rectal cancer trials: statistical evaluation based on the FFCD 9203 trial.

2009

Abstract Background In resectable rectal cancer trials, pathological parameters are early preoperative treatment efficacy measures. Their validation as surrogate end points for long-term clinical outcomes would allow to reduce trial duration. The aim was to evaluate potential surrogates for overall survival (OS) and local control (LC) in preoperative T3/T4 rectal cancer trials. Candidate variables included ypT and ypN stages, T downstaging, tumor regression grade (TRG), and circumferential resection margin (CRM) status. Patients and methods In the Federation Francophone de Cancerologie Digestive (FFCD) 9203 trial, 742 eligible patients were randomly assigned to receive preoperative radiothe…

OncologyAdultMalemedicine.medical_specialtyColorectal cancermedicine.medical_treatmentAdenocarcinomaPreoperative careInternal medicinemedicineHumansNeoadjuvant therapyAgedRandomized Controlled Trials as TopicTumor Regression GradeAged 80 and overbusiness.industrySurrogate endpointRectal NeoplasmsHematologyMiddle Agedmedicine.diseaseChemotherapy regimenCombined Modality TherapyConfidence intervalNeoadjuvant TherapySurgeryClinical trialSurvival RateTreatment OutcomeOncologyFemaleNeoplasm Recurrence LocalbusinessBiomarkersAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Evaluation of pretreatment serum interleukin-6 and tumour necrosis factor alpha as a potential biomarker for recurrence in patients with oral squamou…

2014

Background Oral squamous cell carcinoma (OSCC) constitutes 3 percent of all cancers with predominant occurrence in middle aged and elderly males. Tumour recurrence worsens disease prognosis and decreases quality of life in patients with OSCC. Proinflammatory cytokines such as interleukin-6 (IL-6) and tumour necrosis factor alpha (TNF-α) have been suggested to play a certain role in variety of tumours. The aim of this study was to investigate the relationship of pretreatment serum IL-6 and TNF-α levels on tumour recurrence in patients with OSCC in order to identify potential biomarkers for the early detection of disease recurrence. Material and Methods The patients with newly diagnosed OSCC …

OncologyAdultMalemedicine.medical_specialtyPathologyOdontología03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineCarcinomaSerum IL-6 ; serum TNF-α ; oral cancer ; recurrenceBiomarkers TumorHumansProspective StudiesRisk factorProspective cohort studyGeneral DentistrySurvival analysisEarly Detection of CancerAgedMouth neoplasmOral Medicine and Pathologybusiness.industryInterleukin-6Tumor Necrosis Factor-alphaResearchCancer030206 dentistryMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la salud3. Good healthLog-rank teststomatognathic diseasesOtorhinolaryngology030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASCarcinoma Squamous CellBiomarker (medicine)SurgeryFemaleMouth NeoplasmsNeoplasm Recurrence LocalbusinessMedicina oral, patologia oral y cirugia bucal
researchProduct

Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with epcampositive relapsed or refractory advanced-stage breast…

2012

Background: Targeted therapy options in HER2-negative breast cancer are limited. This open-label, multicenter phase IB dose-escalation trial was conducted to determine safety, tolerability, and antitumor activity of a combination of docetaxel (Taxotere) and increasing doses of adecatumumab, a human IgG1 antibody targeting epithelial cell adhesion molecule (EpCAM), in EpCAM-positive relapsed or primary refractory advanced-stage breast cancer. Patients and methods: Patients pretreated with up to four prior chemotherapy regimens received increasing adecatumumab doses either every 3 weeks (q3w) or weekly (qw) combined with docetaxel (100 mg/m 2 q3w). Primary end points were safety and tolerabil…

OncologyAdultmedicine.medical_specialtyMedizinBreast NeoplasmsDocetaxelAntibodies Monoclonal HumanizedDrug Administration ScheduleBreast cancerAdecatumumabLeukocytopeniaAntigens NeoplasmInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedbusiness.industryLiver NeoplasmsAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseEpithelial Cell Adhesion MoleculeMetastatic breast cancerSurgeryTreatment OutcomeOncologyDocetaxelTolerabilityResponse Evaluation Criteria in Solid TumorsDrug Resistance NeoplasmFemaleTaxoidsBreast diseaseNeoplasm Recurrence LocalbusinessCell Adhesion MoleculesLeukocyte Disordersmedicine.drug
researchProduct

Clinical outcome of recurrent locally advanced cervical cancer (LACC) submitted to primary multimodality therapies

2015

Abstract Objectives Recurrence of disease represents a clinical challenge in cervical cancer patients, especially when all available treatment modalities have been used in the primary setting. The aim of this study was to analyze the patterns of recurrence and their association with clinical outcome in locally advanced cervical cancer (LACC) patients submitted to primary chemoradiation (CTRT) followed by radical surgery (RS). Methods This study was conducted on 364 LACC patients treated with CTRT plus RS since January 1996 to July 2012. For each relapse, information on date of clinical/pathological recurrence, and pattern of disease presentation were retrieved. Post-relapse survival (PRS) w…

OncologyAdultmedicine.medical_specialtyUterine Cervical Neoplasmrecurrent cervical cancerPrognosimedicine.medical_treatmentUterine Cervical NeoplasmsDiseaseObstetrics and gynaecologyRetrospective StudieInternal medicinemedicineHumansRadical surgeryChemoradiation; Post-relapse survival; Prognosis; Radical hysterectomy; Recurrent cervical cancer; Adult; Chemoradiotherapy; Adjuvant; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence; Local; Retrospective Studies; Survival Analysis; Treatment Outcome; Uterine Cervical NeoplasmschemoradiationSurvival analysisNeoadjuvant therapyAdjuvantRetrospective StudiesSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIACervical cancerbusiness.industrypost-relapse survivalObstetrics and GynecologyRetrospective cohort studyChemoradiotherapy AdjuvantChemoradiotherapymedicine.diseaseSurvival AnalysisNeoadjuvant TherapySurgeryLog-rank testTreatment OutcomeNeoplasm RecurrenceSettore MED/40 - GINECOLOGIA E OSTETRICIAOncologyLocalradical hysterectomyFemaleSurvival AnalysiprognosisNeoplasm Recurrence LocalbusinessHuman
researchProduct

Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer: AGO Uterus-4.

2006

Abstract Objective The aim of this phase II multicenter study was to evaluate the safety, toxicity and efficacy of docetaxel administered weekly as first line chemotherapy in patients with recurrent or metastatic endometrial cancer. Patients and methods Thirty five patients with recurrent or metastatic endometrial cancer without previous chemotherapy were enrolled to receive three 6-week cycles of docetaxel 35 mg/m 2 /week with 2-week breaks between the cycles. Therapy response was evaluated after every 6-week cycle, and therapy was continued in case of at least stable disease. Final therapy response was evaluated after three 6-week cycles of docetaxel. Results Thirty five patients with a m…

OncologyAdultmedicine.medical_specialtymedicine.medical_treatmentPhases of clinical researchAntineoplastic AgentsDocetaxelDrug Administration Schedule03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansNeoplasm MetastasisInfusions Intravenous030304 developmental biologyAgedAged 80 and over0303 health sciencesChemotherapybusiness.industryEndometrial cancerObstetrics and GynecologyCancerCombination chemotherapyMiddle Agedmedicine.disease3. Good healthEndometrial NeoplasmsClinical trialOncologyDocetaxel030220 oncology & carcinogenesisToxicityFemaleTaxoidsNeoplasm Recurrence Localbusinessmedicine.drugGynecologic oncology
researchProduct

The Assessment of Risk Factors for Long-term Survival Outcome in ypN0 Patients With Rectal Cancer After Neoadjuvant Therapy and Radical Anterior Rese…

2021

Abstract Background The main negative prognostic factors in patients with rectal cancer after radical treatment include regional lymph node involvement, lymphovascular invasion, and perineural invasion. However, some patients still develop cancer recurrence despite the absence of the above risk factors. The aim of the study was to assess clinicopathological factors influencing long-term oncologic outcomes in ypN0M0 rectal cancer patients after neoadjuvant therapy and radical anterior resection. Methods A retrospective survival analysis was performed on a group of 195 patients. We assessed clinicopathological factors which included tumor regression grade, number of lymph nodes in the specime…

OncologyAnterior rectal resectionmedicine.medical_specialtyRD1-811Lymphovascular invasionColorectal cancermedicine.medical_treatmentPerineural invasion030230 surgeryDisease-Free Survival03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineLymph node yieldHumansLymph nodeNeoadjuvant therapySurvival analysisRC254-282Neoplasm StagingRetrospective StudiesTumor Regression GradeUnivariate analysisbusiness.industryLate anastomotic leakRectal NeoplasmsResearchNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePrognosisNeoadjuvant Therapymedicine.anatomical_structureOncologyStage migration030220 oncology & carcinogenesisSurgeryNeoplasm Recurrence LocalbusinessCharlson comorbidity index
researchProduct

Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review.

2020

Abstract Context Optimal management of prostate cancer (PCa) patients with lymph node invasion at radical prostatectomy and pelvic lymph node dissection still remains unclear. Objective To assess the effectiveness of postoperative treatment strategies for pathologically node-positive PCa patients. The secondary aim was to identify the most relevant prognostic factors to guide the management of pN1 patients. Evidence acquisition A systematic review was performed in January 2020 using Medline, Embase, and other databases. A total of 5063 articles were screened, and 26 studies including 12 537 men were selected for data synthesis and included in the current review according to the Preferred Re…

OncologyBiochemical recurrenceMalemedicine.medical_specialtyUrologymedicine.medical_treatment030232 urology & nephrologyContext (language use)PelvisAndrogen deprivation therapy03 medical and health sciencesProstate cancer0302 clinical medicinePositive nodesInternal medicineMedicineHumansRadiology Nuclear Medicine and imagingStage (cooking)ProstatectomyProstate cancerbusiness.industryProstatectomyLymph node; Positive nodes; Prostate cancer; Radical prostatectomyProstatic Neoplasmsmedicine.diseaseRadical prostatectomyRadiation therapySystematic reviewOncology030220 oncology & carcinogenesisLymphatic MetastasisLymph Node ExcisionSurgeryLymph nodebusinessEuropean urology oncology
researchProduct

Diagnostic efficacy of Gallium-68-PSMA PET/CT in 565 patients with biochemical recurrence of prostate cancer

2019

OncologyBiochemical recurrencemedicine.medical_specialtyProstate cancerchemistrybusiness.industryInternal medicineMedicinechemistry.chemical_elementGalliumbusinessmedicine.diseasePsma pet ct57. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin
researchProduct